New advances in DPYD genotype and risk of severe toxicity under capecitabine. - Wikidata - wikimedia - TriplyDB

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

http://www.wikidata.org/entity/Q33648195

about

PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine.DPYD genotype-guided fluoropyrimidines dose: is it ready for prime time?Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase gene

P2860

Q50067330-7DF636D4-5F76-49BA-ABC5-73B15C29E19D Q50089496-E1842264-AEB9-4BBD-8492-C590E9FC88B0 Q57815793-5A0D83F9-8CB9-496A-936F-8C0C904E1257

P2860

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

http://www.wikidata.org/entity/Q33648195

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

@ast

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

@en

type

label

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

@ast

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

@en

prefLabel

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

@ast

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

@en

P1433

Q33648195-94368ABA-BD68-430A-B1DB-67936983C95A

P1476

Q33648195-EF431BA9-B7E8-4A55-AE2F-87FD508469B2

P2093

Q33648195-049EB3B2-648A-4BEE-B35F-DCB5026165EE

Q33648195-23200828-2185-4AB9-99B4-21D5335731A7

Q33648195-29CB46CC-09FA-4572-8D81-032AB395FEF0

Q33648195-3E40284B-CC2E-40E9-A482-56FF3E138F04

Q33648195-3FDD9C24-CEF6-4D5A-B889-496E8B740DCC

Q33648195-55A6A938-93AF-4ACE-8357-1D309CC31E1C

Q33648195-685C7006-CC37-457D-9405-AAF6AB0F2E83

Q33648195-6BCBEADE-C176-4517-8B07-8AA6E402FC40

Q33648195-781E03B9-9F18-4F17-BC92-8680F18DC853

Q33648195-785AD6D0-420A-42DE-AB1F-163294E0B431

P2860

Q33648195-02888BF7-1E9B-4CB4-9031-00EEF6D51503

Q33648195-0363DA0C-DE22-4BF7-B5B4-589E88C80C76

Q33648195-0CA64C35-476E-4272-848D-FF419B73729E

Q33648195-138556F8-5A71-4686-9D63-5217F9DCBA64

Q33648195-1390EF85-288C-4558-87B4-FCDFC9DB45BC

Q33648195-17B082C6-8C1B-4130-ACF1-808D9DB47DE5

Q33648195-180AB5FA-D3EE-425D-A393-95F902B6A305

Q33648195-3955ADDD-E5CC-4A8F-B48B-01CEACBE5EC8

Q33648195-3B8D9600-DF59-4110-919C-59E69518CC69

Q33648195-3EDB9E6A-79B2-4B06-9713-47EBE31891D0

P304

Q33648195-A2686921-C8BE-42B6-A929-4C2596BA893F

P31

Q33648195-64986F98-30DD-4C52-9136-265C9B95FB63

P356

Q33648195-F56400E8-EFE3-40DD-BA7D-E2300CF433FC

P407

Q33648195-07A59B45-DD07-4EBB-8221-99B7D87B3491

P433

Q33648195-BB7F4B0A-1109-4844-B482-8F5795FA79E5

P478

Q33648195-CF1671E9-33EF-4BEE-B9F3-773119EFC040

P50

Q33648195-A46AE3EA-C8CB-4CC3-A985-97C24761D9F9

Q33648195-D1877146-7E63-4BCA-8360-AC3685E6D111

Q33648195-F18091D4-4F2C-4A61-8B7A-8E29BB9875B4

Q33648195-FB88AC2C-5AD2-4FB4-885B-0178115004F1

P577

Q33648195-FEA8B49A-0526-4581-A7E4-F9B1060AAC3B

P698

Q33648195-0133F1D9-4104-4CBB-B1FA-DF120AC3D0BF

P932

Q33648195-6C1868A0-BCA5-46EA-B1AE-D9FCE2222848

P356

JOURNAL.PONE.0175998

P1433

P1476

New advances in DPYD genotype and risk of severe toxicity under capecitabine

@en

P2093

Alexandre Evrard

http://www.w3.org/2001/XMLSchema#string

André van Kuilenburg

http://www.w3.org/2001/XMLSchema#string

Anthony Goncalves

http://www.w3.org/2001/XMLSchema#string

Christine Bobin-Dubigeon

http://www.w3.org/2001/XMLSchema#string

Christophe Beroud

http://www.w3.org/2001/XMLSchema#string

Christophe Ferrand

http://www.w3.org/2001/XMLSchema#string

Emmanuel Chamorey

http://www.w3.org/2001/XMLSchema#string

Fabienne Thomas

http://www.w3.org/2001/XMLSchema#string

Frédéric Pinguet

http://www.w3.org/2001/XMLSchema#string

Gilles Romieu

http://www.w3.org/2001/XMLSchema#string

P2860

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.

DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

Human Splicing Finder: an online bioinformatics tool to predict splicing signals.

P304

e0175998

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0175998

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Pierre Desvignes

P577

2017-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28481884

http://www.w3.org/2001/XMLSchema#string

P932

5421769

http://www.w3.org/2001/XMLSchema#string